BREL Bioreliance Corp (MM)

Forbes Ranks BioReliance #1 in Earnings Per Share Growth on Annual List of 200 Entrepreneurial Growth Companies ROCKVILLE, Md., Oct. 27 /PRNewswire-FirstCall/ -- BioReliance Corporation announced today that it has been named to Forbes magazine's annual list of "Hot Shots: 200 Up and Coming Companies" for 2003. BioReliance was ranked "Number 1" in Earnings per Share Growth over the past five years and number 139 overall among this select group of smaller public companies. In developing its annual ranking, Forbes collaborated with William O'Neil & Company in the compilation of the list of 200, which consists of fast growing, profitable public companies with revenues between $5 million and $600 million. For the final ranking, equal weight was given to growth in sales, earnings and return on equity for the past five years and the latest 12 months. Appearing for the first time on the annual listing, BioReliance was ranked number 139 overall and "Number 1" in earnings per share growth among the 200 companies comprising the list. Capers McDonald, President and Chief Executive Officer of BioReliance, said, "We are honored in this recognition by Forbes. We believe that it reflects, in part, the high level of dedication by everyone at BioReliance to the productivity and growth of our company. This result, accomplished over the past five years, is driven by our ongoing efforts in quality, science and service. We are committed to providing our customers with the very highest levels of support, wherever we do business, and to increasing shareholder value in that process." About BioReliance BioReliance Corporation is a leading, global contract service organization providing integrated testing, development and manufacturing services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company believes it is the largest provider of outsourcing services focused on the expanding biologics sector of the pharmaceutical industry. This press release contains forward-looking statements that describe certain BioReliance communications. As and when made, management believes that these forward-looking statements are reasonable. BioReliance undertakes no obligation to revise or publicly release the results of any revision to these forward-looking statements. Therefore, readers are cautioned not to place undue reliance on these forward-looking statements since new risk factors emerge from time to time, and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on BioReliance's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. DATASOURCE: BioReliance Corporation CONTACT: John L. Coker, Sr. Vice President, Finance and Administration and Chief Financial Officer of BioReliance Corporation, +1-301-762-5260; or General Info, Marilynn Meek, +1-212-445-8451, or Analysts, Julie Tu, +1-212-445-8456, both of FRB Weber Shandwick

Copyright